Literature DB >> 11245292

Risk factors for cancer development in Helicobacter pylori gastritis.

G Nardone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11245292     DOI： 10.1016/s1590-8658(00)80275-3

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  6 in total

Review 1.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

2.  Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.

Authors:  Nabil Ben Chaabane; Hamad Saadoon Al-Adhba
Journal:  Indian J Gastroenterol       Date:  2015-02-28

3.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

4.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

5.  Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation.

Authors:  Cesare Efrati; Giorgia Nicolini; Claudio Cannaviello; Nicole Piazza O'Sed; Stefano Valabrega
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

6.  Modified Sequential Therapy Regimen versus Conventional Triple Therapy for Helicobacter Pylori Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study.

Authors:  Ying-Qun Zhou; Ling Xu; Bing-Fang Wang; Xiao-Ming Fan; Jian-Ye Wu; Chun-Yan Wang; Chuan-Yong Guo; Xuan-Fu Xu
Journal:  Gastroenterol Res Pract       Date:  2011-11-21       Impact factor: 2.260
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.